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ABSTRACT
 According to breast cancer statistics, 279,100 new cases are expected in the 
United States in 2020 (Siegel et al., 2020). Triple negative breast cancer (TNBC) is the 
most aggressive subtype of breast cancer with a significantly shorter median overall 
survival compared to other subtypes of breast cancer. Unlike hormone-positive or HER2-
positve breast cancers with effective hormonal or targeted therapies available, there has 
been very little clinical success from targeted therapies for TNBC. Doxorubicin (Dox) is 
one of the most used chemotherapy drugs. The only limitation of Dox treatment is its 
cytotoxicity. Berbamine dihydrochloride (BBM) is a natural benzylisoquinoline alkaloid 
that is extracted from the plant, Berbaris amurensis. It has been used in Ayurvedic and 
Chinese medicine to treat clinical patients with inflammation and cancer for many years. 
In order to improve the efficacy of Dox and reduce its toxicity, we screened a natural 
product called BBM that can synergistically inhibit cancer cell growth with Dox in 
TNBC. This study’s aim was to explore the therapeutic potential of the synergism of Dox 
with BBM. In this study, we identified that BBM has a synergistic effect with Dox and it 
increases Dox effectiveness by significantly decreasing the IC50 values of Dox in TNBC. 
We determined that BBM, an autophagy inhibitor, switches the death mode of Dox from 
autophagy to apoptosis. We also determined that BBM increases the extracellular ATP 
secretion and has the potential to trigger immunogenic cell death. These data strongly 
advocate for the therapeutic potential of the efficacy of Dox with BBM in triple negative 
breast cancer.
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CHAPTER 1 
INTRODUCTION
Triple Negative Breast Cancer 
According to an estimation, approximately 1.38 million women get diagnosed 
with breast cancer yearly worldwide (Tomlinson et al., 2014). Breast cancer is 
characterized based on the absence or presence of three main receptors. These receptors 
are estrogen, progesterone, and HER-2. One of the most aggressive types of breast cancer 
is triple negative breast cancer (TNBC), which lacks these three main types of receptors. 
These three receptors usually fuel and provide nutrition to the non-TNBC breast cancers 
(Basu et al., 2008). Since the TNBC lacks the necessary receptors, treatments such as 
therapies and drugs that target estrogen, progesterone, HER-2 receptors cannot be used 
(Paradiso et al., 2017). 
TNBC is the most aggressive subtype of breast cancer, with a significantly shorter 
median overall survival compared to other subtypes of breast cancer. Unlike hormone-
positive or HER2-positve breast cancers with effective hormonal or targeted therapies 
available, there has been very little clinical success from targeted therapies for TNBC 
(Minami et al., 2011). Although TNBC has been assumed the potential protagonist of 
immunotherapy in breast cancer, the earlier studies showed that only 10% of patients 
responded to the therapy (Emens et al., 2019; Adams et al., 2019). The majority of TNBC 
patients still mainly depend on conventional chemotherapy. The two crucial concerns 
with the use of chemotherapy are high toxicity and drug resistance. Once the tumor is 
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resistance to standard chemotherapeutic drugs like anthracyclines or taxanes then only a 
few treatment options are available (Park et al., 2018). 
Chemotherapy is typically designed to kill as many tumor cells as possible with 
the use of maximum tolerated doses (MTD) (Holohan et al., 2013). MTD treatment 
cannot be protracted in order to allow recovery of health tissues and to reduce toxicities. 
For aggressively growing tumors, during these therapeutic breaks, a burst in cell 
proliferation accompanied by manifestation of chemoresistance and accelerated 
angiogenesis are likely. There is an ongoing trend to move from MTD to the low dose 
metronomic (LDM) treatment to achieve optimal clinical outcomes (André et al., 2014; 
Pantziarka et al., 2016; Perroud et al., 2016; Scharovsky et al., 2009). 
 
Doxorubicin 
Doxorubicin (Dox) is one of the most used chemotherapy drugs. It is an 
anthracycline which was originally extracted from Streptomyces peucetius var. caesius in 
the 1970’s, and it is still used today in the treatment of several cancers such as breast, 
gastric, lung, myeloma, ovarian and thyroid (Thorn et al., 2011). Dox is known to do the 
intercalation into the Deoxyribonucleic acid (DNA) and therefore it disrupts the DNA 
repair by inhibiting an enzyme called topoisomerase II. The main function of the 
topoisomerase II is to unwind the DNA during transcription. Cancer cells need this 
enzyme in order to grow and replicate. Hence by inhibiting topoisomerase II, Dox stops 
the cancer progression by slowing down the cancer replication (Gewirtz et al., 1999). 
Recent studies from animal models indicate that Dox, the most used 
chemotherapeutic drug for TNBC, administered in a chronic fashion induces apoptosis of 
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endothelial cells in the tumor microvasculature, therefore, inducing a prolonged 
antiangiogenic effect (Esser et al., 2001). In addition, Dox treatment of tumor cells can 
also induce signals of damage associated molecular pattern (DAMP) that can stimulate 
anti-tumor immunity. The only limitation of Dox treatment is its cytotoxicity (Apetoh et 
al., 2007; Casares et al., 2005; Garg et al., 2017; Ma et al., 2013; Poljaková et al., 2008). 
Dox is a cytotoxic drug. Cytotoxic drugs work by inhibiting the growth cycle and hence it 
effects the cells that grow rapidly (Poljaková et al., 2008). Like, cancer cells some normal 
cells also grow at a faster rate such as hair follicle and hence, in addition, to killing the 
cancer cells, Dox also kills the normal cells. Higher doses of Dox are extremely cytotoxic 
and produce a lot of side effects (Hosseinzadeh et al., 2019). Some common side effects 
of Dox are hair loss, nausea and vomiting, sores in the mouth, darkening of the soles, 
diarrhea, black stools, blood in the urine, pinpoint red spots on the skin, bruising, 
swelling of the feet, shortness of breath, and stomach pain. Majority of these side effects 
are dose dependent, and they get worse with an increase in doses. Because of all these 
side effects, long treatment of Dox with higher doses becomes very difficult (Buranrat et 
al., 2017; Hosseinzadeh et al., 2020). 
 
Paclitaxel 
Similar to Dox, paclitaxel (PAC) is another cytotoxic chemotherapy drug. It 
works by interfering the normal function of microtubules assembly, inhibiting the mitotic 
progression and killing the cancer cells by apoptosis (Jeong et al., 2016). Like Dox, PAC 
also has a lot of side effects such as low blood counts, hair loss, peripheral neuropathy, 
diarrhea, mouth sores, nausea, and vomiting. These side effects make it extremely hard to 
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prescribe PAC for a long period of time. PAC is currently used for breast cancer, cervical 
cancer, Kaposi sarcoma, pancreatic cancer, and lung cancer (Kassi et al., 2019). 
 
Berbamine 
Berbamine dihydrochloride (BBM), a natural benzylisoquinoline alkaloid is 
extracted from the plant, Berbaris amurensis. It occurs as an active constituent in 
numerous medicinal plants and has an array of pharmacological properties. It has been 
used in Ayurvedic and Chinese medicine to treat clinical patients with inflammation and 
cancer for many years (Wang et al., 2009). BBM has been reported to have antitumor 
activities in various types of cancers, including myeloma, breast and lung cancers, 
especially targeting cancer stem cells (Gu et al., 2012; Hong et al., 2016; Liang et al., 
2009; Yang et al., 2014). BBM has been found to inhibits autophagy by blocking the 
fusion between lysosome and autophagosome (Figure 1.2). Autophagy is a cellular 
recycling and self degradative process. The main role of autophagy is to degrade 
damaged organelle and misfolded proteins. Cancer cells sometimes uses autophagy as a 
tool for survival by getting rid of damaged organelles. BBM inhibits the autophagy and 
stops the cancer survival (Fu et al., 2018). 
 
ER Stress 
Recent studies have shown that Dox induces the endoplasmic reticulum stress and 
kills the cancer cells by autophagy, apoptosis and immunogenic cell death (Bagchi et al., 
2018; Casares et al., 2005; Wang et al., 2004; Xiao et al., 2019). The endoplasmic 
reticulum (ER) is a cellular organelle which is found in all eukaryotic cells. The main 
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function of the ER to is to synthesize and fold the protein. The balance between the 
protein synthesis and protein folding must be met for the ER to function properly (Hosoi 
et al., 2015). The physiological stresses can increase the synthesis of the protein. As the 
protein synthesis get increased it overwhelms the ER capacity to fold proteins. This over 
production of proteins and disruption of the ER homeostasis results in the misfolding and 
unfolding of the proteins (Xu et al., 2005). The accumulation of unfolded proteins 
activates the unfolded protein response (UPR), which is a cellular stress response that 
leads to the ER stress (Igwebuike et al., 2020). The UPR is carried out mainly by 2 ER 
effector proteins. Protein kinase like endoplasmic reticulum kinase (PERK) and the 
inositol requiring enzyme 1 (IRE1α). During the physiological state, in the absence of 
UPR, PERK and IRE1α activation is suppressed by an ER chaperone called glucose 
regulated protein 78 (GRP78). Under normal condition, both PERK and IRE1α are 
bounded by GRP78, which inhibits their phosphorylation. During ER stress, GRP78 
dissociates from PERK and IRE1α and binds to the unfolded proteins in order to refold 
them back into their proper folding state (De la Cadena et al., 2013). In addition to the ER 
stress, another protein called eukaryotic initiation factor 2 (eIF2α) plays an important role 
in cell survival. The phosphorylation of the eIF2α at serine 51 is a well studied 
mechanism which results in the inhibition of protein translation. The downregulation of 
P-eIF2α reflects that the protein synthesis is increased which usually results in the 
accumulation of misfolded proteins and hence causing the ER stress (Muaddi et al., 
2010). Both PERK and IRE1α are important markers of the ER stress while the P- eIF2α 
indicates the attenuation of protein synthesis (Badiola et al., 2011). 
 
6 
Autophagy 
Autophagy is a type of cell death in which the damaged cytosolic components are 
degraded by lysosomes. Autophagy plays an extremely significant role in cell survival 
(Glick et al., 2010). The macroautophagy (herein referred to as autophagy) is a highly 
conserved type of the autophagy in which a double membrane bound vesicles called 
autophagosomes engulfs the intracellular organelles and proteins. These autophagosomes 
are then delivered to lysosomes where they fuse with lysosomes for degradation (Kogel, 
2015). The autophagy begins by the formation of the phagophore assembly site (PAS), 
the elongation of the PAS gives rise to the phagophore. A phagophore is a double 
membrane structure that encloses the damaged cytosolic components and misfolded 
proteins into a vesicle and this vesicle is called an autophagosome. These 
autophagosomes are then fused with the lysosomes for degradation (Figure 1.1). This 
fusion process is called autolysosome and it is the last stage of autophagy (Kaur et al., 
2015). 
In general, the autophagy is divided into three stages. The early stage, the middle 
stage, and the later stage. The early stage is the formation of phagophores. Beclin-1 is a 
protein which detects the expressions of these phagophore in this early stage of the 
autophagy. The middle stage is the formation of the autophagosomes. The autophagy 
related protein 12 (ATG-12) is a protein which detects the expressions of the 
autophagosomes in the middle stage of the autophagy. The later and the final stage is the 
fusion of the autophagosomes and lysosome where the degradation of the damaged 
organelles and misfolded proteins take places. LC3B-I detects the expressions of the 
autophagosomes in the later stage, and LC3B-II serves as an indicator of autolysosome of 
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autophagy (Kaur et al., 2015). During autophagy, non-lipidated soluble LC3B-I gets 
converted to phosphatidylethanolamine conjugated LC3B-II, which serves as an 
important and sensitive indicator of autophagy (Klionsky et al., 2016). 
The main goal of the autophagy is to alleviate stress from the cells by removing 
the damaged organelles and misfolded proteins. Therefore, autophagy plays an important 
role in cell survival. Recent evidences have shown that autophagy can protect cancer cells 
from metabolic stresses because of its survival role (Alirezaei et al., 2010; Parzych et al., 
2014; Zhang et al., 2009). Under normal conditions, autophagy occurs when SNAP29 
interacts with STX17 and VAMP8, which drives autophagosome and lysosome fusion. 
BBM upregulates the expression of a protein called BCL-2 Interacting Protein 3 
(BNIP3), which contains homology to BCL-2. BNIP3 can interact and inhibit the 
SNAP29 interaction with VAMP8, hence it inhibits the autophagy by blocking 
autophagosome and lysosome fusion (Figure 1.2). Autophagy helps to alleviate stress by 
the degradation of the damaged organelles and misfolded proteins. Recent evidence has 
shown that sometimes cancer cells use autophagy for cell survival. BBM inhibits the 
autophagy and hence stops the survival of cancer cells (Fu et al., 2018). 
 
Apoptosis 
Apoptosis is a type of programmed cell death. During apoptosis cells go through 
some morphological changes. Apoptotic cells start to shrink in size, which forces all the 
cell organelles to get tightly packed together (Figure 1.3). The cell membrane of these 
cells starts blebbing and eventually activates an essential executioner of apoptosis called 
caspase 3 (Elmore et al., 2007). During apoptosis, the executioner caspase 3 gets cleaved 
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by an initiator caspase (Caspase 2, Caspase 8, Caspase 9, or Caspase 10). The cleaved 
caspase 3 is an extremely important marker of apoptosis. During apoptosis, the cellular 
constituents of cells are not released into the surrounding by apoptotic cells. Apoptosis is 
a highly controlled type of programmed cell death, which does not lead to inflammation. 
(Porter et al., 1999). 
There are two types of pathways of apoptosis, intrinsic and extrinsic pathways. In 
intrinsic pathways, cells sense the internal stress stimuli and respond to these signals by 
initiating apoptosis. These stress signals mostly include the DNA damage and 
biochemical stress signals. In extrinsic pathways, cells sense the external stress stimuli 
and responds to these external signals by initiating apoptosis (Fulda et al., 2006). Another 
type of apoptosis is called caspase 3 independent form of apoptosis. Recent studies have 
shown that a flavoprotein called apoptosis inducing factor (AIF), that is found in 
mitochondria, can induce apoptosis by a caspase 3 independent mechanism. Both the 
caspase 3 dependent and independent types of apoptosis have similar morphological 
features (Bai et al., 2015; Mansilla et al., 2005). Dox is known to disrupt the DNA repair 
through inhibiting an enzyme called topoisomerase II. The higher doses of Dox cause the 
DNA damage in cancer cells and activate the apoptosis through the intrinsic pathway. 
Most of the major therapies such as chemotherapy, immunotherapy and γ-irradiation kill 
the tumor by initiating apoptosis (Synowiec et al., 2015; Wang et al., 2004; Zhong et al., 
2017). 
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Immunogenic cell death 
Immunogenic cell death (ICD) is another type of cell death. The ICD is a 
specialized form of cell death that is characterized by the expression of damage 
associated molecular patterns (DAMPs) that are found in tumor microenvironments. The 
goal of ICD is to elicit an immune response. Some hallmarks of ICD are extracellular 
Adenosine triphosphate (ATP) release, exposure of calreticulin (CRT) on the cell surface 
and phagocytosis. The extracellular ATP release serves as find-me signals, to stimulate 
anti-cancer immunity (Garg et al., 2012; Zhou et al., 2019). The extracellular ATP is 
released by lysosomal exocytosis. This mechanism requires lysosomal associated 
membrane protein 1 (LAMP 1), which translocate to plasma membrane in a caspase 3 
and pannexin 1 depended manner. The extracellular ATP release serves as find-me signal 
and macrophage detects this extracellular ATP signal by the help of a receptor called 
purinoceptor 2 (P2Y2) (Adamson et al., 2017; Martins et al., 2013; Radogna et al., 2018; 
Wang et al., 2013). The CRT is a chaperone that resides in the lumen of the ER. During 
ER stress, the phosphorylation of PERK and IRE1α leads to the translocation of CRT 
from the lumen of the ER to the surface of the cell. This translocation of CRT serves as 
eat-me signals for macrophages. The goal of the extracellular ATP release and 
translocation of CRT to the cell surface is for the macrophages to find these apoptotic 
cells and eat them. A recent study has shown that late stage autophagy inhibition 
enhances the CRT surface exposure (Li et al., 2016). The extracellular ATP release, 
translocation of CRT on the cell surface and phagocytosis serves as the important 
markers for ICD (Bezu et al., 2018; Feng et al., 2018; Garg et al., 2012; Keep et al., 2009; 
Obeid et al., 2006; Osman et al., 2017). 
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Hypothesis 
The goals of this project were to see if the natural product BBM can be used in a 
synergistic manner with Dox to increase its efficacy. Dox is a cytotoxic chemotherapy 
drug and higher doses of Dox produces a lot of side effects (Hosseinzadeh et al., 2019). 
We wanted to see if BBM can enhance the effectiveness of Dox and if their combined 
therapy could be used to reduce Dox concentrations by decreasing its half maximal 
inhibitory concentration (IC50 value). The IC50 value represents the concentration of a 
drug that is required for it to reach the 50% inhibition of a specific biological function in 
vitro. In addition, we also wanted to find out if the synergism of BBM is just limited to 
Dox or if BBM could also has a synergistic effect with another chemotherapy drug called 
PAC and if its efficacy could also be increased. 
The hypothesis of my research was that the natural product BBM can increase the 
efficacy of Dox by decreasing its IC50 values in TNBC. BBM can also increase the 
effectiveness of Dox by inhibiting the autophagy and switching the cell death mode to 
apoptosis. In addition, BBM also has the potential to induce ICD. 
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Figure 1.1: Overview of mammalian autophagy pathways. The macroautophagy 
initiates with the formation of the PAS. The elongation of the PAS gives rise to the 
phagophore. The phagophore expressions could be detected by Beclin-1. A 
phagophore is a double membrane structure that encloses the damaged cytosolic 
components and misfolded proteins into a vesicle and this vesicle is called an 
autophagosome. The autophagosome expressions could be detected by the ATG-12. 
This autophagosome are then fused with the lysosome for degradation. This fusion 
process is called autolysosome. LC3B serves as an indicator of autolysosome and 
hence it is a sensitive indicator for autophagy. This figure has been taken from (Kaur 
et al., 2015). 
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Figure 1.2: The proposed mechanism of BBM-mediated blockade of 
autophagosome and lysosome fusion. Under normal conditions, SNAP29 
interacts with STX17 and VAMP8, which drives autophagosome and lysosome 
fusion. BBM upregulates the expression of BNIP3, which can interact and inhibit 
the SNAP29 interaction with VAMP8, hence it blocks the autophagosome and 
lysosome fusion. This figure has been taken from (Fu et al., 2018). 
13 
 
 
Figure 1.3: Morphology of apoptotic cell. It is a photomicrograph of a section of 
exocrine pancreas from B6C3F1 mouse. The arrows indicate apoptotic cells which are 
shrunk and condensed with cytoplasm. This figure has been taken from (Elmore et al., 
2007). 
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CHAPTER 2 
MATERIALS AND METHODS
Cell Culture and Reagents 
Hs578T and MDA-MB-231 are human triple negative breast cancer cell lines. 
These cell lines were purchased from ATCC. Both cell lines were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) (GE Healthcare Life Sciences), which contained 4 
mM L-Glutamine, 4,500mg/L glucose and sodium pyruvate. In addition, 10% FBS and 
1% of antibiotic antimycotic solution (10,000 ug/mL penicillin, 10,000 ug/mL 
streptomycin, and 25 ug/mL Amphotericin B) (Mediatech, Inc) were added to DMEM. 
Both cell lines were maintained at 37°C with 5% CO2 in a humidified incubator. 
THP-1 is a human monocyte cell line. This cell line was obtained from Dr. Jun 
Zhu, University of South Carolina. This cell line was cultured in Iscove's Modified 
Dulbecco's Medium (IMDM) (GE Healthcare Life Sciences), which contained 4 mM L-
Glutamine and HEPES. In addition, 10% FBS and 1% of antibiotic antimycotic solution 
(10,000 ug/mL penicillin, 10,000 ug/mL streptomycin, and 25 ug/mL Amphotericin B) 
(Mediatech, Inc) were added to IMDM. This cell line was also maintained at 37°C with 
5% CO2 in a humidified incubator. 
Dox (Cat number 25316-40-9) was purchased from Cayman Chemicals and it was 
dissolved in the Dimethyl sulfoxide (DMSO). PAC (Cat number 193532) was purchased 
from MP Biomedicals and it was dissolved in DMSO. BBM (Cat number 6078-17-7) was 
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purchased from Sigma-Aldrich and it was also dissolved in DMSO. The experiments 
were performed by treating the cells with Dox or BBM or Dox and BBM combined. 
 
MTT Assay 
MTT is an assay to examine cell viability. Hs578T and MDA-MB-231 cells were 
seeded at a density of 35,000 cells/well in triplicate in a 24 well plates. These cells were 
treated with Dox or BBM or Dox and BBM combined or PAC or PAC and BBM 
combined or DMSO for 24 hours. At the end of the incubation, media was removed, and 
MTT assay reagent called 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
was added in each well at the final concentration of 1mg/mL per well. These plates were 
incubated for 3 hours at 37°C with 5% CO2 in a humidified incubator. At the end of the 
incubation, media was removed, and the formazan precipitates were dissolved by adding 
400 μl of DMSO in each well. OD values were measured at both 570 and 630 nm and 
final values were calculated by subtracting OD630 from OD570. The average values of 
each sample were used to plot the growth curve by using Microsoft Excel. 
 
Western Blot 
 Hs578T and MDA-MB-231 cells were seeded at a density of 150,000 cells/well in 
in a 12 well plate. These cells were treated with Dox or BBM or Dox and BBM combined 
or DMSO for 24 hours. At the end of the incubation, media was removed, and protein 
extracts were obtained from whole cell lysates. The protein was isolated by using cell 
lysis buffer, which contained Sodium orthovanadate, sodium fluoride, protease inhibitor 
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(Sigma), and mammalian protein extraction reagent (M-PER) (Thermofisher). This lysis 
buffer was used following the manufacturer’s instructions.  
The protein quantification was performed by a Bradford assay. A mixture of 1 µL 
of protein and 9 µL of deionized water was added in a 96 well plate in triplicate. 10 µL of 
protein standards were added in the concentrations of 0.125 mg/mL, 0.25 mg/mL, 0.5 
mg/mL, 0.75 mg/mL, and 1 mg/mL. 150 µL of Coomassie protein assay reagent 
(Thermofisher) was added into each well of the 96 well plate. This plate was incubated in 
the dark for 10 minutes at room temperature. At the end of the incubation, a plate reader 
was used to read the results at 595 nm wavelength. A plot of protein standards was 
created in Microsoft Excel and protein concentrations of each sample was calculated 
based on the standards. 
The proteins were denatured by adding the 6X Laemmli sample buffer and 
bringing its final concentration to 1X. All protein samples were boiled at 100°C for ten 
minutes for complete denaturation. The proteins samples and precision plus protein 
ladder (Bio-Rad) were loaded on a 12% acrylamide gels and these gels were loaded into 
the reservoir chamber (Bio-Rad). The reservoir chamber was filled with 1X protein 
running buffer (3 g Tris-HCl, 14.4 g glycine, 1 g SDS) and ran at 100 V for 2 hours at 
room temperature. Prior to transfer the gel, the transfer gel cassette (Bio-Rad) was 
assembled with two sponges, two pieces of filter paper, a piece of nitrocellulose paper 
(GE Healthcare Life Sciences). The transfer gel cassette was set up in the following 
order, from front to back: cassette, sponge, filter paper, gel, nitrocellulose membrane, 
filter paper, sponge, cassette. The cassette was closed and placed into the reservoir 
chamber along with an ice pack. The reservoir chamber was filled with 1X protein 
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transfer buffer (3 g Tris, 14.4 g glycine, and 10% methanol). The reservoir chamber was 
run at 230 mA for 1.5 hours at 4°C. After the gel transfer was complete the nitrocellulose 
membranes were removed and placed in the blocking buffer made of 5% milk (Nestle 
Carnation Instant Dry Milk, 20 g/L) mixed with Tris buffered saline-Tween 20 (TBST). 
These nitrocellulose membranes were incubated in the blocking buffer for 1 hour. At the 
end of the incubation, the nitrocellulose membranes were rinsed three times with TBST. 
These nitrocellulose membranes were then probed with primary antibodies. All 
the primary antibodies were made in 5% bovine serum albumin (BSA) mixed with TBST 
in 1:1000 ratio (Table 2.1). The nitrocellulose membranes were incubated in primary 
antibodies overnight at 4°C on an orbital shaker. At the end of the incubation, these 
membranes were rinsed three times with TBST and then they were probed with HRP 
linked secondary antibody for 1 hour at room temperature on an orbital shaker. At the end 
of the incubation, these membranes were rinsed again three times with TBST. These 
membranes were finally removed from the TBST using tweezers and incubated in a 1:1 
ratio mixture of either west pico plus chemiluminescent substrate (ThermoFisher 
Scientific) or west femto maximum sensitivity substrate (ThermoFisher Scientific) for 5 
minutes. At the end of the incubation, these membranes were loaded on a cling wrap into 
the ImageQuant LAS 4000 biomolecular imager (GE Healthcare Life) and the results 
were visualized according to optimal settings (Table 2.2). As the internal control for 
equal loading, a GAPDH (Santa Cruz Biotechnology) control was performed on each 
nitrocellulose membrane. Western blot images were quantified using GE ImageQuant 
Software. 
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ATP Quantification Assay 
 A Luminescent ATP Detection Assay Kit was purchased from Abcam (Cat no. 
ab113849). This kit was used to measure the extracellular ATP secretion. Hs578T and 
MDA-MB-231 cells were seeded at a density of 50,000 cells/well in 24 well plates. These 
cells were treated with Dox or BBM or Dox and BBM combined or DMSO for 24 hours. 
At the end of the incubation, media from each sample in the plates was moved into the 
microcentrifuge tubes. The media in these microcentrifuge tubes was gently mixed by 
pipetting up and down. A mixture of 50 µL of media and 25 µL of ATP substrate per 
sample was added together into the new microcentrifuge tubes. These tubes were 
incubated in the dark for 2 hours at room temperature. The ATP standards were also 
prepared in the concentrations of 0 µM, 0.0001 µM, 0.001 µM, 0.01 µM, 0.1 µM, 1 µM, 
10 µM and 100 µM according to the manufacture protocol. At the end of the incubation, 
media was removed and a luminometer machine was used to read the results. A plot of 
the ATP standards was created in Microsoft Excel and ATP concentration of each sample 
was calculated based on the standards. 
 
Phagocytosis Assay 
 100,000 THP1 cells were added into ten 50 mm petri dishes. These cells were 
differentiated into macrophages for 3 days by adding 300nM of phorbol 12-myristate 13-
acetate (PMA) per petri dish. These cells were maintained at 37°C with 5% CO2 in a 
humidified incubator. At the end of the incubation, macrophages were scraped off the 50 
mm petri dishes. 
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Hs578T and MDA-MB-231 petri dishes were trypsinized by adding 0.25% 
trypsin-ethylenediaminetetraacetic acid (EDTA) solution (Mediatech) for 5 minutes in 
each petri dish. After the cells were trypsinized, they were neutralized with DMEM in 1:1 
ratio. These cells were centrifuged at 500 (RCF) for 5 minutes at room temperature and 
then the cells were resuspended in new DMEM. These cells were counted with the help 
of a hemocytometer by adding trypan blue solution 0.4% (Thermo Fisher Scientific) into 
the cells. 5000,000 cells from each cell line were stained by adding 0.5 µL of cell tracker 
deep red dye (Life Technologies). These cells were incubated in the dark for 30 minutes. 
Both cell lines were seeded in a 1:3 ratio in 12 well plates (1 ratio of Hs578T or MDA-
MB-231 and 3 ratios of macrophages), while keeping the total number of cells constant at 
150,000 per well. After the cells were adhered to the surface of the plate overnight, they 
were treated with Dox or BBM or Dox and BBM combined or DMSO for 15 hours. 
These cells were maintained at 37°C with 5% CO2 in a humidified incubator.  
At the end of the incubation, macrophages were co-cultured with Hs578T and 
MDA-MB-231 in a 1:3 ratio as previously described. These cells were also maintained at 
37°C with 5% CO2 in a humidified incubator. At the end of the incubation, these cells 
were centrifuged at 500 RCF and then they were resuspended in 100 µL of 2% FBS. 
These cells were labeled with FITC anti-mouse/human CD11b antibody (BioLegend) at a 
concentration of 1:100 ratio and incubated for 1 hour on ice. At the end of the incubation, 
these cells were centrifuged at 500 RCF and then they were resuspended in 100 µL of 2% 
FBS. The fluorescence activated cell sorting (FACS) analysis was performed on these 
samples by using the flow cytometer. The results were analyzed based on cell tracker 
deep red eye and CD11b antibody. In FACS results, the CD11b (specific to 
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macrophages) was shown in FL1-A fluorescence channel and deep red dye (specific to 
Hs578T and MDA-MB-231) was shown in FL4-A fluorescence channel. 
 
Statistical Analysis 
The statistical analyses were conducted with Microsoft Excel. All data were 
shown as the mean ± standard deviation (SD). P-value of comparisons of two groups 
were analyzed using the two-tailed t-test. P-values of p < 0.05, p < 0.01, and p < 0.001 
are indicated with (*), (**), and (***), respectively, and all considered statistically 
significant. 
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Table 2.1: The western blot antibodies 
 
Antibody Concentration 
Ratio 
Manufacturer Catalog No. 
P-eIF2α 1:1000 Cell Signaling 3398T 
PERK 1:1000 Cell Signaling 5683T 
IRE1α 1:1000 Cell Signaling 3294T 
Beclin-1 1:1000 Cell Signaling 3495T 
ATG-12 1:1000 Cell Signaling 4180T 
LC3B 1:1000 Cell Signaling 3868S 
Cleaved Caspase 3 1:1000 Cell Signaling 9664S 
GAPDH 1:1000 Santa Cruz 
Biotechnology 
SC-32233 
Anti-rabbit HRP 
Linked 
1:3000 Cell Signaling 7074P2 
Anti-mouse HRP 
Linked 
1:3000 Cell Signaling 7076S 
 
  
Table 2.1: This table shows all the primary and secondary antibodies that were used 
in Western Blot. This table also show the concentration ratio, manufacturer and 
catalog number of all the antibodies. 
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Table 2.2: Optimal exposure settings for western blot detection 
 
Element Setting 
Exposure type Precision 
Exposure time Auto 
Resolution Standard 
Digitization of image On 
Method/Tray position 1 
Method Chemilumination 
Table 2.2: All samples were viewed using the ImageQuant LAS 4000 biomolecular 
imager (GE Healthcare Life Sciences). The above settings were used for each western 
blot. 
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CHAPTER 3 
RESULTS
Efficacy of Dox and PAC with BBM 
The experiments were initiated by first screening the BBM to determine if BBM 
has any effect on cell growth of TNBC by itself. Hs578T cells were treated with BBM (5 
µM,10 µM, 20 µM, and 30 µM) for 24 hours. At the end of the incubation, MTT assay 
was performed to examine cells viability (Figure 3.1 A). We concluded that BBM by 
itself does not significantly inhibit the cell growth of Hs578T cells. The next steps were 
to screen some of the most common chemotherapy drugs; Dox and PAC along with 
BBM. We started the next experiment with Dox. Hs578T cells were treated with Dox (1 
µM, 2.5 µM, 5 µM, and 10 µM) or BBM (5 µM,10 µM, 20 µM, and 30 µM) or Dox and 
BBM combined or DMSO for 24 hours. Cell viability was conducted by MTT assay 
(Figure 3.1 B). The results showed that BBM synergistically increased the efficacy of 
Dox. Different doses of Dox and BMM was chosen to determine the best possible 
concentrations of this synergetic relationship between Dox and BBM. We noticed that 
BBM acted synergistically with Dox in a dose dependent manner as the cell viability 
values decreased with an increase in BBM concentration. The Dox 1µM average cell 
viability value without the BBM was 78 percent and the Dox 1µM and BBM 5 µM, 10 
µM, 20 µM, and 30 µM combined average values were 69, 62, 56, 54 respectively. BBM 
20 µM and 30 µM cells viability values were extremely close. This implied that BBM 
synergism might get less effective after the 20 µM concentration. In this experiment, the 
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results explained that the BBM 20 µM was the best concentration for the Dox and BBM 
synergistic relationship. The next sets of experiments were performed by keeping the 
BBM constant at 20 µM. 
The next experiment was performed with PAC and BBM. Hs578T cells were 
treated with PAC (10 nM, 25 nM, 50 nM, 100 nM, 150 nM, and 200 nM) or BBM (20 
µM) or BBM and PAC combined or DMSO for 24 hours. At the end of the incubation, 
the cell viability was calculated by MTT assay (Figure 3.2 A). The results showed that 
BBM also has a synergistic relationship with PAC. Similar to Dox, BBM also acted 
synergistically with PAC in a dose dependent manner as the cell viability decreased with 
an increase in PAC concentration, in the presence of BBM. The BBM significantly 
decreased the PAC IC50 value. The IC50 value of PAC, without the BBM, was reached 
by PAC 50 nM, while the IC50 value with PAC and BBM combined was reached by 
PAC 25 nM (Figure 3.2 B). These results concluded that BBM increased the PAC 
efficacy by lowering its IC50 value. 
Since the BBM concentration was now kept fixed at 20 µM, another series of 
experiment was performed with different concentrations of Dox and BBM. The goal of 
this experiment was to observe morphological changes of cells and to determine the best 
contractions of Dox and BBM for further studies. Hs578T cells were treated with Dox (1 
µM, 2.5 µM, 5 µM, 10 µM, 20 µM, 30 µM, 40 µM) or BBM (20 µM) or Dox and BBM 
combined or DMSO for 24 hours. At the end of the incubation, the cell viability was 
calculated by MTT assay (Figure 3.3 A). The results showed that BBM was more 
effective with Dox as compared to PAC. The BBM significantly decreased the IC50 
value of Dox. The IC50 value with Dox without the BBM was reached by Dox 10 µM. 
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While IC50 value with Dox and BBM combined was reached by Dox 2.5 µM (Figure 3.3 
B). We also noticed some morphological changes in cells treated with Dox without BBM 
as compared to the cells treated with Dox and BBM combined. The cells treated with 
Dox 1 µM without BBM appeared in clusters and looked inflamed while the cells that 
were treated with Dox 1 µM and BBM combined appeared in insolated patches and did 
not look inflamed. In Dox 5 µM without BBM, this clusters went away, and cells 
appeared more in insolated patches while the cells that were treated with Dox 5 µM and 
BBM combined appeared in very small insolated patches, and majority of cells appeared 
shrink with dense cytoplasm around them (Figure 3.4 A). In summary, these 
morphological changes suggested that BBM perhaps reduced the inflammation and 
changed the death mode of the cells. The morphology of cells that were treated with Dox 
5 µM without the BBM looked similar to the cells that were treated with Dox 1 µM and 
BBM combined. These results indicated that perhaps the cells that were treated with Dox 
5 µM without the BBM and that were treated with Dox 1 µM and BBM combined were 
dying from the same cell death pathway. 
We decided to further pursue BBM experiments with Dox. The reason we chose 
Dox as compared to PAC was because recent studies showed that Dox might have more 
potential in therapy because it can induce ER stress and kill cancer cells by autophagy, 
apoptosis and ICD (Bagchi et al., 2018; Casares et al., 2005; Wang et al., 2004; Xiao et 
al., 2019). In addition, the IC50 values from the results indicated that BBM was more 
effective with Dox as compared to PAC.  
To further study the relation of Dox and BBM we chose another TNBC cell line 
called MDA-MB-231 to perform the MTT assay. The MDA-MB-231 cells were treated 
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with Dox (1 µM, 2.5 µM, 5 µM, 10 µM, 20 µM, 30 µM, 40 µM) or BBM (20 µM) or 
Dox and BBM combined or DMSO for 24 hours. At the end of the incubation, the cell 
viability was again calculated by MTT assay (Figure 3.3 C). BBM was also very effective 
with Dox in MDA-MB-231 cell line as it significantly decreased the IC50 value. The 
IC50 value with Dox without the BBM was reached by Dox 5 µM. While IC50 value 
with Dox and BBM combined was reached by Dox 2.5 µM (Figure 3.3 D). The 
morphology of MDA-MB-231 cells looked different as compared to the morphology of 
Hs578T cells. The cells treated with Dox 1 µM without the BBM did not looked inflamed 
and they looked similar to the cells that were treated with Dox 1 µM and BBM combined. 
In Dox 5 µM without the BBM, these cells also looked similar to the cells that were 
treated with Dox 5 µM and BBM combined. The majority of cell treated Dox 5 µM and 
BBM combined, appeared to shrink with dense cytoplasm around them (Figure 3.4 B). In 
summary, these different morphological changes suggested that BBM cell death 
pathways were perhaps different in Hs578T and MDA-MB-231. 
 
Effects of Dox with BBM on ER Stress 
The next experiments were designed to study the ER stress, autophagy and 
apoptosis related proteins. Both Hs578T and MDA-MB-231 cells were treated with Dox 
(1 µM, 2.5 µM, 5 µM, 10 µM) or BBM (20 µM) or Dox and BBM combined or DMSO 
for 24 hours. Western blot analysis was used at the end of the treatment to study the 
protein expressions of both cell lines. The two main ER stress proteins are PERK and 
IRE1α. Under normal condition, both PERK and IRE1α are bounded by GRP78 which 
inhibits their phosphorylation. During ER stress, GP78 dissociates from PERK and 
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IRE1α and binds to the unfolded proteins in order to refold them back into their proper 
folding state (De la Cadena et al., 2013). In addition to the ER stress another protein 
called P-eIF2α plays an important role in cell survival. Phosphorylation of the eIF2α at 
serine 51 is a well studied mechanism which results in the inhibition of protein 
translation. The downregulation of P-eIF2α reflects that the protein synthesis is increased 
which usually results in the accumulation of misfolded proteins and hence causing the ER 
stress (Muaddi et al., 2010). 
The Hs578T western blot results showed that both PERK and IRE1α were 
downregulated in Dox with BBM combined doses. The expressions of both the PERK 
and IRE1α were observed at its peak in Dox 1 µM and BBM combined dose. The P-
eIF2α expressions showed that the protein translation was inhibited in both the lower and 
higher Dox with BBM combined doses. In summary, these results indicated that the ER 
stress was at its peak in lower concentration while in higher concentrations of Dox with 
BBM combined, the ER stress was going down. The P-eIF2α expressions indicated that 
the protein translation was inhibited at both lower and higher concentration of Dox with 
BBM combined doses (Figure 3.5 A). The MDA-MB-231 western blot results showed 
that both PERK and IRE1α were also downregulated in Dox with BBM combined doses. 
The expressions of both the PERK and IRE1α in MDA-MB-231 was different as 
compared to the Hs578T. In MDA-MB-231, the ER stress proteins expressions were not 
at its peak in Dox 1 µM and BBM combined dose as previously observed in Hs578T. The 
P-eIF2α expression was downregulated in Dox 1 µM and BBM combined dose and it was 
upregulated in the higher doses of Dox with BBM combined (Figure 3.5 B). In summary, 
these results showed that ER stress was going down in both lower and higher doses of 
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Dox with BBM combined. The protein synthesis was accelerated in Dox 1 µM and BBM 
combined dose, but it was inhibited in higher concentrations of Dox with BBM 
combined. 
 
Effects of Dox with BBM on Autophagy 
Autophagy is divided into three stages. The early stage, the middle stage, and the 
later stage. The early stage is the formation of phagophores. The Beclin-1 is a protein 
which detects the expressions of these phagophore in this early stage of the autophagy. 
The middle stage is the formation of the autophagosomes. The ATG-12 is a protein 
which detects the expressions of the autophagosomes in the middle stage of the 
autophagy. The later and the final stage is the fusion of the autophagosomes and 
lysosome where the degradation of the damaged organelles and misfolded proteins take 
places. LC3B-I detects the expressions of the autophagosomes in the later stage, and 
LC3B-II serves as an indicator of autolysosome of autophagy. Thus, LC3B-II serves as a 
sensitive indicator of autophagy (Kaur et al., 2015).  
Hs578T results indicated that Beclin-1 expressions went down in the dose 
dependent manner, the lower doses of Dox with BBM combined has higher expressions 
of Beclin-1 as compared to the higher doses of Dox with BBM combined. These 
expressions explained that phagophore formation was increased in lower doses of Dox 
with BBM combined as compared to the higher doses of Dox with BBM combined. The 
ATG-12 expressions were not significantly changed in lower doses of Dox with BBM 
combined, but they were decreased slightly in higher doses of Dox with BBM combined. 
These results indicated that the autophagosomes formation went down in the higher dose 
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of Dox with BBM while at the lower dose of Dox with BMM, there was no significant 
change in the autophagosomes formation. The final stage of the autophagy was studied 
by the conversion of the LC3B-I to LC3B-II, which is the fusion of the autophagosomes 
and lysosome that leads to degradation. Because of the degradation, down regulation of 
LC3B-II expressions serves as an indicator that cell died by the autophagy. No significant 
expressions of LC3B-II were observed in Dox concentrations without the BBM, 
indicating that Dox without the BBM was killing the cancer cells by autophagy. In Dox 
with BBM combined, the LC3B-II expression was at peak in Dox 1 µM and BBM 
combined, and its expressions started to downregulate in higher doses of Dox with BBM 
combined. These results indicated that the lower doses of Dox with BBM combined 
inhibited the autophagy, while at the higher doses of Dox with BBM combined, the 
inhibition of autophagy got reversed and cell started to die by autophagy (Figure 3.5 A). 
In summary, in the lower doses of Dox with BBM combined, the phagophores and 
autophagosomes expressions were not significantly changed. The highest peak of LC3B-
II was observed in Dox 1 µM with BBM combined, this peak indicated that the 
autophagy was inhibited. In the higher doses of Dox with BBM combined, the 
phagophore and autophagosomes expressions were decreased. The LC3B-II signals were 
downregulated indicating that inhibition of autophagy was reversed, and cell were dying 
by autophagy. 
The MDA-MB-231 results indicated that there was not a significant change in the 
expressions of Beclin-1 and ATG-12 in the cells that were treated with Dox with BBM 
combined, indicating that phagophore and autophagosomes expressions were not 
significantly changed. The LC3B-II expressions were observed in all the Dox with BBM 
30 
combined doses, indicating that the autophagy was entirely blocked throughout the 
treatment. In summary, both the lower and higher doses of the Dox with BBM combined 
had similar effects. The phagophores and autophagosomes expressions were not 
significantly changed and the autophagy was entirely inhibited (Figure 3.5 B). 
 
Effects of Dox with BBM on Apoptosis 
During apoptosis, the executioner caspase 3 gets cleaved by an initiator caspase 
(Caspase 2, Caspase 8, Caspase 9, or Caspase 10). The cleaved caspase 3 is an extremely 
important marker of apoptosis. Another type of apoptosis is called caspase 3 independent 
form of apoptosis. Recent studies have shown that a flavoprotein called AIF, that is found 
in mitochondria, can induce apoptosis by a caspase 3 independent mechanism. Both the 
caspase 3 dependent and independent types of apoptosis have similar morphological 
features (Bai et al., 2015; Mansilla et al., 2005).   
Hs578T results showed that in Dox without the BBM treatment, cleaved caspase-
3 expressions only appeared in Dox 10 µM, while in cells treated by Dox with BBM 
combined, low expressions of cleaved caspase 3 started to appear in Dox 1µM with BBM 
combined and these expressions were upregulated in a dose dependent manner. The Dox 
5 µM with BBM combined, showed very significant upregulation of the cleaved caspase 
3 expressions, indicating that the addition of BBM with Dox treatment changes the Dox 
cell death mode from autophagy to apoptosis. These results also indicated that the BBM 
started to change the cell death mode and initiated the apoptosis in both the lower and 
higher doses of the Dox (Figure 3.5 A). The MDA-MB-231 results showed that that the 
cleaved caspase 3 expression was at peak at Dox 1 µM and BBM combined, and its 
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expressions started to downregulate in higher doses of Dox with BBM combined. These 
results indicated that the lower doses of Dox with BBM combined triggered the caspase 3 
dependent apoptosis while higher doses of Dox with BBM combined, perhaps triggered 
the apoptosis through caspase 3 independent pathway (Figure 3.5 B). The GAPDH was 
used as the loading control for the western blot and all the protein expressions were 
normalized based on the GAPDH expressions. 
In summary, the Hs578T results showed that the both lower and higher doses of 
Dox with BBM combined triggered the caspase 3 dependent apoptosis. The MDA-MB-
231 results showed that lower doses of Dox with BBM combined triggered the caspase 3 
dependent apoptosis while higher doses of Dox with BBM combined perhaps triggered 
the caspase 3 independent apoptosis. 
 
Effects of Dox with BBM on ICD 
The goal of the ATP quantification experiments was to determine if the BBM had 
the potential to trigger ICD by increasing the extracellular ATP secretion. ICD is a 
specialized form of cell death that is characterized by the expression of the DAMPs that 
are found in tumor microenvironments. The goal of ICD is to elicit an immune response. 
Some hallmarks of ICD are extracellular ATP release, exposure of CRT on the cell 
surface and phagocytosis. The extracellular ATP release serves as find-me signals, to 
stimulate anti-cancer immunity. The extracellular ATP is released by lysosomal 
exocytosis. This mechanism requires lysosomal associated membrane protein 1 (LAMP 
1), which translocate to plasma membrane in a caspase 3 and pannexin 1 depended 
manner (Garg et al., 2012; Zhou et al., 2019). 
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Hs578T and MDA-MB-231 cells were treated with Dox (1 µM, 2.5 µM, 5 µM, 10 
µM, 20 µM) or BBM (20 µM) or Dox and BBM combined or DMSO for 24 hours. At the 
end of the incubation, the extracellular ATP quantification was measured. Hs578T results 
indicated that the lower doses of Dox with BBM combined did not significantly triggered 
the secretion of the extracellular ATP while the higher doses of the Dox with BBM 
combined triggered the secretion of the extracellular ATP. The extracellular ATP 
secretion started to increase at Dox 5 µM and BBM combined. The cleaved caspase 3 is 
required along with the autophagy triggered the secretion of the ATP (Figure 3.6 A). At 
Dox 5 µM and BBM combined, cleaved caspase 3 expressions were upregulated, and 
autophagy was also observed, hence all the conditions were met for the secretion of the 
extracellular ATP. In summary, the lower doses of Dox with BBM combined did not 
trigger the secretion of the extracellular ATP while the higher doses of Dox with BBM 
combined triggered the secretion of the extracellular ATP.  
The MDA-MB-231 results showed that the extracellular ATP secretion was not 
significantly triggered by the Dox with BBM combined doses (Figure 3.6 B). This ATP 
pattern was not proportional to the cleaved caspase 3 pattern of Dox 1 µM and BBM 
combined. In addition to the cleaved caspase 3 the secretion of the extracellular ATP also 
requires the autophagy. In Dox 1 µM and BBM combined, the western blot results 
indicated that the autophagy was entirely inhibited throughout the treatment. Hence, these 
results showed that the extracellular ATP was not secreted because both conditions of the 
ATP secretion were not met. In addition to the inhibition of autophagy, the higher doses 
of Dox with BBM combined did not also trigger the secretion of the extracellular ATP 
because the cell perhaps died through caspase 3 independent form of apoptosis. 
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The phagocytosis assay was performed to determine if the macrophages could 
track the secretion of ATP from the apoptotic cells. The extracellular ATP release serves 
as find-me signal and macrophage detects this extracellular ATP signal by the help of a 
P2Y2 receptor (Adamson et al., 2017; Martins et al., 2013; Radogna et al., 2018; Wang et 
al., 2013). CRT is a chaperone that resides in the lumen of the ER. During ER stress, the 
phosphorylation of PERK and IRE1α leads to the translocation of CRT from the lumen of 
the ER to the surface of the cell. This translocation of CRT serves as eat-me signals for 
macrophages. The goal of the extracellular ATP release and translocation of CRT to the 
cell surface is for the macrophages to find these apoptotic cells and eat them. A recent 
study has shown that late stage autophagy inhibition enhances the CRT surface exposure 
(Li et al., 2016). The extracellular ATP release, translocation of CRT on the cell surface 
and phagocytosis serves as the markers for the ICD. 
 The Hs578T and MDA-MB-231 cells were treated with Dox (1 µM, 5 µM) or 
BBM (20 µM) or Dox and BBM combined or DMSO for 15 hours and co-culture with 
macrophages for 3 hours. At the end of the incubation, the phagocytosis assay was 
performed by FACS. The results were analyzed by staining both Hs578T and MDA-MB-
231 cells by the cell tracker deep red dye and macrophages were labeled with FITC anti-
mouse/human CD11b. In FACS, the CD11b (specific to macrophages) was shown in 
FL1-A fluorescence channel and deep red dye (specific to Hs578T and MDA-MB-231) 
was shown in FL4-A fluorescence channel. 
 The Hs578T results showed that the number of macrophages eating the apoptotic 
cells was increased in dose dependent manner. The Dox 5 µM and BBM combined had 
the highest peak. This peak was proportional to the extracellular ATP secretion. The 
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phagocytosis was also observed in Dox 1 µM and BBM combined (Figure 3.7 A and B). 
This phagocytosis expression was not proportional with the extracellular ATP secretion, 
but the western blot results showed that in Dox 1 µM and BBM combined both ER stress 
proteins PERK and IRE1α were phosphorylated and the later stage autophagy was 
blocked. All these results indicated that the Dox 1 µM and BBM combined phagocytosis 
was perhaps led by CRT exposure to the cell surface. The MDA-MB-231 results did not 
show any significant phagocytosis (Figure 3.7 C and D). These results were proportional 
with the extracellular ATP release and the western blots results did not show the 
phosphorylation of ER stress proteins either.  
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Figure 3.1: MTT of Hs578T cells with Dox and different BBM concentrations 
treatment. Hs578T cells were treated with BBM (5 µM, 10 µM, 20 µM, 30 µM) (A) 
and Dox (1 µM, 2.5 µM, 5 µM, 10 µM) or Dox and BBM combined or DMSO for 24 
hours (B). At the end of the treatment, MTT assay reagent called 3-(4, 5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was used to examine the cells 
viability. P-values of p < 0.05, p < 0.01, and p < 0.001 are indicated with (*), (**), and 
(***), respectively, and all considered statistically significant. 
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Figure 3.2: MTT of Hs578T cells with PAC and BBM treatment. Hs578T cells 
were treated with PAC (10 nM, 25 nM, 50 nM, 100 nM, 150 nM, 200 nM) or BBM 
(20 µM) or Dox and BBM combined or DMSO for 24 hours (A and B). At the end of 
the treatment, MTT assay reagent called 3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide was used to examine the cells viability. P-values of p < 
0.05, p < 0.01, and p < 0.001 are indicated with (*), (**), and (***), respectively, and 
all considered statistically significant. 
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Figure 3.3: MTT of Hs578T and MDA-MB-231 cells with Dox and BBM 
treatment. Hs578T and MDA-MB-231 cells were treated with Dox (1 µM, 2.5 µM, 5 
µM, 10 µM, 20 µM, 30 µM, 40 µM) or BBM (20 µM) or Dox and BBM combined or 
DMSO for 24 hours (A, B, C and D). At the end of the treatment, MTT assay reagent 
called 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was used to 
examine the cells viability. P-values of p < 0.05, p < 0.01, and p < 0.001 are indicated 
with (*), (**), and (***), respectively, and all considered statistically significant. 
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Figure 3.4: Morphological changes of Hs578T and MDA-MB-231 
cells with Dox and BBM treatment. Hs578T and MDA-MB-231 
cells were treated with Dox (1 µM, 5 µM) or BBM (20 µM) or Dox 
and BBM combined or DMSO for 24 hours (A and B). These images 
were captured by a compound microscope at the end of the treatment. 
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Figure 3.5: Western Blot of Hs578T and MDA-MB-231 cells with Dox and 
BBM treatment. Hs578T and MDA-MB-231 cells were treated with Dox (1 µM, 
2.5 µM, 5 µM, 10 µM) or BBM (20 µM) or Dox and BBM combined or DMSO for 
24 hours. Western blot analysis was used at the end of the treatment to show the 
protein expressions of ER stress, autophagy, and apoptosis related proteins (A and 
B). P-eIF2α, PERK, and IRE1α are ER stress proteins. Beclin-1, ATG-12, and 
LC3B 1 and 2 are autophagy proteins. Cleaved caspase 3 is an apoptosis protein. 
GAPDH was used as a loading control. 
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Figure 3.6: The extracellular ATP quantification of Hs578T and MDA-MB-231 cells 
with Dox and BBM treatment. Hs578T and MDA-MB-231 cells were treated with Dox 
(1 µM, 2.5 µM, 5 µM, 10 µM, 20 µM) or BBM (20 µM) or Dox and BBM combined or 
DMSO for 24 hours. At the end of the treatment, extracellular ATP quantification was 
measured (A and B). P-values of p < 0.05, p < 0.01, and p < 0.001 are indicated with (*), 
(**), and (***), respectively, and all considered statistically significant. 
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Figure 3.7: Phagocytosis assay of Hs578T and MDA-MB-231 cells 
with Dox and BBM treatment. Hs578T and MDA-MB-231 cells were 
treated with Dox (1 µM, 5 µM) or BBM (20 µM) or Dox and BBM 
combined or DMSO for 15 hours and co-cultures with macrophages for 3 
hours. At the end of the incubation, the phagocytosis assay was performed 
by doing FACS (A, B, C, and D). P-values of p < 0.05, p < 0.01, and p < 
0.001 are indicated with (*), (**), and (***), respectively, and all 
considered statistically significant. 
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CHAPTER 4 
CONCLUSION
Efficacy of Dox and PAC with BBM 
The goal of this study was to determine if BBM can enhance the efficacy of 
chemotherapy drugs. The first step was to screen chemotherapy drugs and we started by 
screening some of the most common chemotherapy drugs; Dox and PAC. These 
chemotherapy drugs were chosen because of their ability to inhibit the cell growth and 
induce apoptosis. The Hs578T and MDA-MB-231 cell lines were chosen for the 
experiments because they are aggressive TNBC cell lines. 
The efficacy of BBM was determined by MTT assays. The BBM concentration 
was fixed at 20 µM because of its effectiveness with Dox. The BBM synergism was more 
effective in Dox as compared to the PAC because Dox with BBM combined IC50 value 
was significantly lower as compared to the PAC with BBM combined IC50 value. The 
efficacy of Dox was increased by the BBM in both the TNBC cell lines; Hs578T and 
MDA-MB-231. The morphological changes were different in Hs578T as compared to the 
MDA-MB-231, indicating that the cells were perhaps dying of different cell death 
pathways. 
 
Effects of Dox with BBM on ER Stress, Autophagy, and Apoptosis 
The ER stress, autophagy and apoptosis effects were determined by western blot. 
The western blot results of Hs578T showed that the ER stress was caused in the lower 
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doses of Dox with BBM combined, because of the inhibition of the autophagy. The 
autophagy was responsible to degrade the misfolded proteins and since the autophagy 
was inhibited the misfolded proteins initiated the UPR and hence causing the ER stress. 
The ER stress went away in the higher doses of Dox with BBM combined because the 
autophagy inhibition was reversed, and cells were dying by both the autophagy and 
apoptosis. The results of the treatment of Dox without the BBM showed that the majority 
of the cells were only dying from the autophagy while the addition of BBM showed that 
in the lower doses the cell death mode was switched from autophagy to caspase 3 
dependent apoptosis and in higher doses the cells were dying by both the autophagy and 
the caspase 3 dependent apoptosis. The western blot results of MDA-MB-231 showed 
that the ER stress expressions were not significantly increased in the lower doses of Dox 
with BBM combined. These results explained that even when the autophagy was 
inhibited the misfolded proteins were not accumulated because the cells were dying by 
apoptosis. The LC3B-II expressions explained that the autophagy was inhibited 
throughout the entire treatment of Dox with BBM combined. The cleaved caspase 3 
expressions were downregulated in a dose dependent manner. These results indicated that 
the lower doses of Dox with BBM combined triggered the caspase 3 dependent apoptosis 
while higher doses of Dox with BBM combined, perhaps triggered the caspase 3 
independent apoptosis. 
 
Effects of Dox with BBM on ICD 
 The extracellular ATP secretion and phagocytosis are the important hallmarks of 
ICD. The results showed that the Hs578T extracellular ATP pattern was different as 
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compared to the MDA-MB-231. In Hs578T, the lower doses of Dox with BBM 
combined did not trigger the extracellular ATP secretion while the higher doses of Dox 
with BBM combined triggered the secretion of the extracellular ATP. The Hs578T 
phagocytosis results showed that the lower doses of Dox with BBM combined perhaps 
led the phagocytosis by the CRT exposure to cell surface caused by the ER stress and late 
stage autophagy inhibition. The higher doses of Dox with BBM combined led the 
phagocytosis by the secretion of the extracellular ATP. In MDA-MB-231, the 
extracellular ATP secretion was not significantly increased by both the lower and higher 
doses of Dox with BBM combined. This is because both the cleaved caspase 3 and 
autophagy are required for the secretion of the extracellular ATP. The autophagy was 
inhibited throughout the BBM treatment and hence it did not increase the extracellular 
ATP secretion significantly. The MDA-MB-231 results also did not show any significant 
phagocytosis activity. These results were proportional with the extracellular ATP 
secretion and ER stress led CRT cell surface exposure because neither the extracellular 
ATP secretion nor the ER stress was significantly observed by Dox with BBM combined 
treatment. 
 
Conclusion 
In conclusion, this study’s aim was to explore the therapeutic potential of the 
synergism of Dox with BBM. The MTT assay results showed that that BBM has a 
synergistic effect with Dox and it increases Dox efficacy by significantly decreasing the 
IC50 values of Dox in both Hs578T and MDA-MB-231 cell lines. Because of BBM’s 
ability of decreasing the IC50 value of Dox, the combinational treatment of Dox with 
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BBM could be used to decrease the Dox concentration without compromising its 
effectiveness. The decrease in the Dox concentration would also decrease its cytotoxicity 
and side effects. The western blot results showed that BBM, an autophagy inhibitor, 
switches the cell death mode of Dox from autophagy to apoptosis. Recent studies have 
shown that certain breast cancers become resistant to Dox chemotherapy (Han et al., 
2019; Lovitt et al., 2018). The combined treatment of Dox with BBM could also be used 
to switch the cell death mode from autophagy to apoptosis and hence it perhaps could be 
used to treat the chemoresistance of certain breast cancers. In Hs578T, the extracellular 
ATP results showed that BBM increases the extracellular ATP secretion. The 
phagocytosis assay showed that the extracellular ATP secretion served as find-me signals 
for macrophages and it has the potential to trigger ICD. In Hs578T, the combined 
treatment of Dox with BBM killed the cancer cells by three different types of cell deaths: 
autophagy, apoptosis and ICD. The MDA-MB-231 cells perhaps died by two different 
forms of apoptosis: caspase 3 dependent and caspase 3 independent apoptosis. 
The BBM future studies could be done on finding the specific cell death pathways 
and trying to understand the role of BBM in switching the cell death mode from 
autophagy to apoptosis in Dox. Further chemotherapy drugs could also be studied to 
figure out if BBM could also increase the efficacy of more chemotherapy drugs. In 
addition, in vivo studies could be done to study the synergistic effects of BBM with Dox 
and its ICD potential. These data strongly advocate for the therapeutic potential of the 
efficacy of BBM with Dox in triple negative breast cancer.
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